Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This Phase 1 escalating-dose study is designed to assess, the safety, tolerability,
pharmacokinetics, and pharmacodynamics of the novel proteasome inhibitor CEP 18770, given
intravenously as single agent, in patients with advanced, incurable solid tumours or NHL, and
to identify the recommended dose of CEP 18770 to be used in Phase 2 studies.